3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Hepatocellular
19
Stomach Neoplasms
12
Colorectal Neoplasms
10
Rectal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Esophageal Squamous Cell Carcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Endometrial Neoplasms
2
Turcot syndrome
1
Thyroid Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Spinocerebellar Degenerations
1
Sarcoma
1
Salivary Gland Malignant Neoplasms
1
Resectable NSCLC
1
Recurrence
1
Rare Tumor
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms
1
NSCLC
1
Microsatellite Stable Metastatic Colorectal Cancer
1
Metastatic Gastroesophageal Junction Adenocarcinoma
1
Interventions
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
9
Cyclophosphamide
9
Prednisone
8
Doxorubicin
7
Vincristine
6
Azacitidine
5
pembrolizumab
3
fludarabine
3
belinostat
3
Lenalidomide
3
Brentuximab Vedotin
3
10-propargyl-10-deazaaminopterin
3
ruxolitinib
2
duvelisib
2
Gemcitabine
2
Dexamethasone
2
Biopsy
2
Bendamustine Hydrochloride
2
venetoclax
1
spartalizumab
1
somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)-
1
sodium-iodide symporter
1
sintilimab
1
pomalidomide
1
ixazomib
1
ivarmacitinib
1
daratumumab
1
cemiplimab
1
calaspargase pegol
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, T-Cell, Peripheral
×
sintilimab
×
Clear all
NCT04512534
2026-04-02
Sincerely20
Fudan University
Phase 2
Recruiting
51 enrolled